- Company to host Key Opinion Leader webinar today, September 12, at 1:30 pm CT/2:30 pm ET -
LYON, France and CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced positive efficacy and safety data from the first cohort of its ongoing Phase 2a study of AZP-3601 in patients with hypoparathyroidism at the American Society for Bone and Mineral Research 2022 Annual Meeting (ASBMR), which is being held September 9-12 in Austin, TX.
During three months of treatment with AZP-3601, mean serum calcium levels were maintained within the target range and allowed for the discontinuation of oral calcium and active vitamin D supplementation in most patients. Normalization of urinary calcium was rapidly achieved in all patients, including those with hypercalciuria at baseline, together with restoration of balanced bone resorption/formation activity. AZP-3601 was well tolerated and demonstrated a favorable safety profile.
We are very pleased with the compelling results from the first patient cohort of this ongoing trial, said Mark Sumeray, M.D., chief medical officer of Amolyt Pharma. The data demonstrate that the mechanism of action of AZP-3601 translates into important potential clinical benefits for patients with hypoparathyroidism, in particular those with or at risk of developing hypercalciuria, osteopenia or osteoporosis, who represent the majority of patients with this disease. We look forward to results from Cohort 2, which will inform the design of a Phase 3 trial as we work to advance this promising therapeutic peptide through an efficient late-stage development plan.
Key findings:
The study was a three-month multi-center open-label design. Following an optimization period of up to eight weeks during which calcium and active vitamin D supplementation were adjusted to achieve baseline albumin-adjusted serum calcium (AdsCa) within the range of 7.8 to 9.0mg/dL, patients received a daily subcutaneous (sc) administration of 20g AZP-3601 for 28 days, while simultaneously reducing their calcium and active vitamin D intake. Further up-titration to a maximum dose of 60 g/d was recommended if needed to achieve AdsCa within the target range.
Thierry Abribat, Ph.D., founder and chief executive officer of Amolyt Pharma, added, With AZP-3601, our key underlying assumption is that intermittent administration of this PTH analog targeting the R0 conformation of the PTH receptor would induce a long-acting effect on serum Ca, mainly through a potent and sustained effect on Ca reabsorption in the kidney, while stimulating resumption of normal bone metabolism, thus preserving bone minerality. These data support this assumption, outlining a potentially new clinical profile, which we believe is ideally suited to address the needs of patients with hypoparathyroidism.
Oral Presentation Details:Title: Efficacy and Safety of AZP-3601, a Novel Investigational Long-Acting PTH Analog for Treatment of Hypoparathyroidism. Results From the First Cohort of a 3-Month Multi-Center Open Label Phase 2a StudyFormat: Late-breaking oral presentationDate: Monday, September 12, 2022Session time: 11:30 am-12:45 pm CT (12:30 pm-1:45 pm ET)Presentation time: 11:30 am-11:45 am CT (12:30 pm-12:45 pm ET)Author/Presenter: Istvan Takcs, M.D. (Semmelweis University, Budapest, Hungary), author and lead investigator of the study
Investor webinar:Amolyt will host a KOL webinar to discuss these Phase 2a results in more detail today, September 12, 2022, at 1:30 pm CT/2:30 pm ET. Interested parties can register for the webinar here.
About Hypoparathyroidism Hypoparathyroidism is defined by a deficiency of parathyroid hormone (PTH) that results in decreased calcium and elevated phosphorus levels in the blood. Approximately 80% of the estimated 80,000 people in the U.S. and 110,000 in the European Union with hypoparathyroidism are women. Despite available treatments, patients experience persistent, life-altering symptoms and often develop complications and comorbidities that diminish quality of life and create segments of the patient population with specific clinical needs. Clinical manifestations of hypoparathyroidism impact many tissues and organ systems, in particular, the kidneys and bone. 17% of patients with hypoparathyroidism have osteopenia or osteoporosis and 53% are peri- or postmenopausal women with an increased risk of developing osteoporosis. Approximately 26% of patients with hypoparathyroidism have chronic kidney disease or failure, highlighting the importance of reducing urinary calcium excretion as a key treatment goal.
About AZP-3601AZP-3601 is an investigational therapeutic peptide designed to target a specific conformation of the parathyroid hormone (PTH) receptor to safely produce sustained and stable levels of calcium in the blood and thereby manage the symptoms of hypoparathyroidism, and to limit urine calcium excretion by restoring calcium reabsorption by the kidney, with the goal of consequently preventing chronic kidney disease. In addition to its unique receptor profile, AZP-3601 is also designed to have a short half-life to potentially preserve bone integrity, an important benefit, since many patients are peri- and postmenopausal women with an increased risk of developing osteoporosis.
About Amolyt PharmaAmolyt Pharma, a clinical stage biotechnology company, is building on its teams established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its development portfolio includes AZP-3601, a long-acting PTH analog as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. To learn more, visit https://amolytpharma.com/ or follow us on Twitter and LinkedIn.
Go here to read the rest:
- Acute Effects of Growth Hormone on the Cellular Immunologic Landscape in Pediatric Patients - Cureus - April 2nd, 2024
- The Role of Growth Hormone Mediators in Youth-Onset T2D - Medscape - March 13th, 2024
- Detecting human growth hormone: the ITA launches a targeted project ahead of Paris 2024 - International Testing Agency - February 22nd, 2024
- Role of the Growth Hormone Receptor (GHR) Gene in Skeletal Class II Malocclusion and Its Significant Influence on ... - Cureus - February 12th, 2024
- Alzheimer's passed to patients by human growth hormone taken from corpses - The Telegraph - February 2nd, 2024
- Human growth hormone shots from cadavers linked to Alzheimer's, study finds - NBC News - February 2nd, 2024
- Study says thousands of Americans who received growth hormone may be at risk of Alzheimers - Fox News - February 2nd, 2024
- Growth hormone given to kids may be linked to Alzheimer's, study shows - UPI News - February 2nd, 2024
- Human growth hormone treatments given decades ago linked to five cases of Alzheimers - KIRO Seattle - February 2nd, 2024
- Growth Hormone Treatment May Have Transmitted Alzheimer's to Children, Study Warns - AboutLawsuits.com - February 2nd, 2024
- Researchers find tie between banned growth hormone and Alzheimer's - Gwinnettdailypost.com - February 2nd, 2024
- HGH Over The Counter: Updated Insights into Accessing Human Growth Hormone Supplements - Deccan Herald - February 2nd, 2024
- Adverse event reports of growth hormone injections on the rise - KBR - February 2nd, 2024
- Alzheimers revelation: How the brain disease was spread between humans via a growth hormone given to children in the UK up until 1985 - The Olive... - February 2nd, 2024
- HGH Over The Counter 2024: Exploring Access to Human Growth Hormone Supplements - Deccan Herald - February 2nd, 2024
- Researchers find tie between banned growth hormone and Alzheimer's - Newsbug.info - February 2nd, 2024
- Banned Hormone Given to Children With Growth Deficiencies Linked to Alzheimer's Disease, Researchers Say - MSN - February 2nd, 2024
- Human growth hormone therapy linked with pediatric tibial physeal avulsion fractures - Healio - January 7th, 2024
- Human Growth Hormone Market Size to be Worth USD 3.9 billion by 2031, with Notable CAGR of 3.7 %| Transparency ... - Yahoo Finance - January 7th, 2024
- HSS Study Reveals Concerning Link Between Growth Hormone Therapy and Growth Plate Fractures in Children - OrthoSpineNews - January 7th, 2024
- Growth hormone found to influence regulation of anxiety via a specific group of neurons - Medical Xpress - January 7th, 2024
- Normal Physiology of Growth Hormone in Adults - Endotext - NCBI Bookshelf - November 19th, 2023
- "I admired the effort he made to continue" - Lionel Messi's ex-teammate gives rare insight into PSG superstar's growth hormone treatment -... - April 21st, 2023
- Abdu Rozik witnesses a 'miraculous' growth in his height; learn all about growth hormone deficiency - Times of India - April 13th, 2023
- Growth Hormone Deficiency (GHD): Symptoms & Treatment - Cleveland Clinic - January 28th, 2023
- Acromegaly - Symptoms and causes - Mayo Clinic - January 20th, 2023
- Growth hormone-releasing hormone | You and Your Hormones from the ... - January 11th, 2023
- Growth Hormone in Sport: What Athletes Should Know | USADA - January 11th, 2023
- Growth Hormone Deficiency | Boston Children's Hospital - January 11th, 2023
- Cortisol - Wikipedia - January 11th, 2023
- Adult Growth Hormone Deficiency | Cedars-Sinai - December 25th, 2022
- Growth Hormone Deficiency | Endocrine Society - December 25th, 2022
- Plant hormone - Wikipedia - December 16th, 2022
- Growth hormone | Definition, Function, Deficiency, & Excess - December 16th, 2022
- Growth Hormone Deficiency: Causes, Symptoms & Diagnosis - Healthline - December 16th, 2022
- Growth Hormones Fed to Beef Cattle Damage Human Health - November 30th, 2022
- Growth hormone - Better Health Channel - November 21st, 2022
- Growth Hormone Tests: Protocol, Costs, Results, and More - Healthline - October 25th, 2022
- 7 amazing things that happen to your body while you sleep - October 17th, 2022
- Growth Hormone -Types, Regulation & Growth Hormone Function - BYJUS - October 17th, 2022
- Hormone Changes: The Star of Every Stage in Women's Sleep - Medscape - October 17th, 2022
- Bigg Boss 16's Abdu Rozik suffers from Growth Hormone deficiency, all you need to know - DNA India - October 17th, 2022
- 3 of the World's Tallest Men Ever Recorded Lived in Our DayAnd Some Are Still Towering Over Us Today - The Epoch Times - October 17th, 2022
- Navy SEAL leaders reprimanded over trainee's death in 'Hell Week' - Los Angeles Times - October 17th, 2022
- New Technology Developments in Protein Therapeutics Market to Grow during Forecast year 2022-2030 | Abbott Laboratories, Amgen Inc., Baxter... - October 17th, 2022
- Down and Out in Paradise review a disservice to Anthony Bourdain - The Guardian - October 17th, 2022
- Discovery Of Family Of Hormones May Be Key To Increased Crop Yields - Eurasia Review - October 17th, 2022
- How Will the World Cup Shape Lionel Messis Legacy? - GQ - October 17th, 2022
- "Henry Cejudo is finished" Fans hilariously react to internet celebrity Hasbulla Magomedov signing a deal with the UFC - Sportskeeda - October 17th, 2022
- "It isnt quite like playing, but its the closest thing to it. You remember every pitch" - Legendary broadcaster Bob Costas on his comeback... - October 17th, 2022
- Understand the different functions of pituitary gland - Telangana Today - October 17th, 2022
- 'How Hormone Replacement Therapy Impacted My Strength Training' - Women's Health - October 9th, 2022
- Nugenix Total T Reviews - Why We Are Disappointed With This T Booster - Deccan Herald - October 9th, 2022
- Is Inflammation Good for Muscle Growth? And Does it Help to Eat Your Protein Before Your Vegetables? - STACK - October 9th, 2022
- Nairobi Student With Kidney Infection, Stunted Growth in Desperate Need of KSh 1.4m for Treatment - Tuko.co.ke - October 9th, 2022
- Zerodha CEO Nithin Kamath practises 12-hour fastingbut is that good for your health? - The Indian Express - October 9th, 2022
- 5 Health Risks You Face Due to Lack of Sleep - News18 - October 9th, 2022
- Acromegaly Market Size was USD 1326.6 million in 2021 and it is expected to rise during the study period (2019-2032) - Digital Journal - September 30th, 2022
- Aaron Judge Ties the Real Home Run Record - Rolling Stone - September 30th, 2022
- The Global Protein Therapeutics Market size is expected to reach $490.2 billion by 2028, rising at a market growth of 6.9% CAGR during the forecast... - September 30th, 2022
- Patents to biological medicines in combination: is two really better than one? - Lexology - September 30th, 2022
- Biosimilars Market to reach a size of US$ 100.5 Bn by the end of 2032 - GlobeNewswire - September 30th, 2022
- PCOS awareness: Know how it is linked to diabetes and secondary infertility - Health shots - September 30th, 2022
- Top 7 benefits of olive oil for hair growth and ways to use it - PINKVILLA - September 30th, 2022
- Growth hormone in IVF: the endometrial effect - ESHRE - September 22nd, 2022
- 7 Everyday Foods To Avoid For Healthy Skin - Evie Magazine - September 22nd, 2022
- Health Beat: NEC in preemies | Health Beat | wfmz.com - 69News WFMZ-TV - September 22nd, 2022
- Popular YouTubers The Boys geek out over Hasbulla for 15 minutes straight - We Got This Covered - September 22nd, 2022
- Livestock bred with growth promoters unhealthy for consumption Prof Adetunji - Punch Newspapers - September 22nd, 2022
- Targeted Therapy to Treat Cancer - The Epoch Times - September 22nd, 2022
- I tried popular weight loss diet for two weeks heres the surprising things I learned... - The US Sun - September 22nd, 2022
- Dr. Oz Returns with the Momentum to Take Out Fetterman - The Clay Travis & Buck Sexton Show - September 22nd, 2022
- Complicated Urinary Tract Infections Market to Witness Growth at a CAGR of 5.9% by 2032 | DelveInsight - PR Newswire - September 14th, 2022
- 6 Signs You're Aging Faster Than You Should Eat This Not That - Eat This, Not That - September 14th, 2022
- Triple-Negative Breast Cancer Treatment Market to Experience Significant Growth During the Forecast Period 2026 - BioSpace - September 14th, 2022
- Like it or not, e-bikes on Hilton Head are here - Charleston Post Courier - September 14th, 2022
- Biosimilars Global Market Opportunities and Strategies Report 2022: Long-term Forecast to 2026 & 2031 - ResearchAndMarkets.com - Business Wire - September 6th, 2022
- Lumos Pharma to Participate in the HC Wainwright 24th Annual Global Investment Conference - GuruFocus.com - September 6th, 2022
- Role of Sirtuins in Diabetes and Age-Related Processes - Cureus - September 6th, 2022
- The Global External Fixation Systems Market to Witness Growth at a CAGR of 5.62% During the Study Period (20192027) | DelveInsight - Yahoo Finance - September 6th, 2022